Global Information
회사소개 | 문의

알츠하이머병 : 파이프라인 리뷰

Alzheimer´s Disease - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 232776
페이지 정보 영문 1333 Pages
가격
US $ 2,500 ₩ 2,870,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,740,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,610,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


알츠하이머병 : 파이프라인 리뷰 Alzheimer´s Disease - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 1333 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

알츠하이머병은 진행성 질환으로, 서서히 증상이 악화되어 가며, 신경이 침범되어 기억과 행동에 장애가 일어납니다. 신경은 신호 전달의 원인이 되는 신경전달물질 아세틸콜린을 합성하기 때문에 파괴되면 신호 전달이 단절되어 결과적으로 기억과 행동 기능에 장애가 발생합니다. 연령, 유전, 순환기질환, 당뇨병, 환경적 요인 등 다양한 요인에 의해 알츠하이머병 발병 위험이 높아집니다. 다양한 합병증을 일으키기도 하며, 치료하지 않고 방치해 두면 치명적일 수도 있습니다.

알츠하이머병(Alzheimer's Disease) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업 및 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 알츠하이머병 개요

치료제 개발

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 상황 개요

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

치료제 평가

치료제 개요

최근의 파이프라인 동향

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

LSH 16.04.21

List of Tables

  • Number of Products under Development for Alzheimer's Disease, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Alzheimer's Disease - Pipeline by AB Science SA, H2 2018
  • Alzheimer's Disease - Pipeline by AbbVie Inc, H2 2018
  • Alzheimer's Disease - Pipeline by AC Immune SA, H2 2018
  • Alzheimer's Disease - Pipeline by Accera Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Affichem SA, H2 2018
  • Alzheimer's Disease - Pipeline by AFFiRiS AG, H2 2018
  • Alzheimer's Disease - Pipeline by Alector LLC, H2 2018
  • Alzheimer's Disease - Pipeline by Allergan Plc, H2 2018
  • Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Allinky Biopharma SL, H2 2018
  • Alzheimer's Disease - Pipeline by ALSP Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Alzinova AB, H2 2018
  • Alzheimer's Disease - Pipeline by AlzProtect SAS, H2 2018
  • Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Amgen Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H2 2018
  • Alzheimer's Disease - Pipeline by Annexon Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Aphios Corp, H2 2018
  • Alzheimer's Disease - Pipeline by Apodemus AB, H2 2018
  • Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H2 2018
  • Alzheimer's Disease - Pipeline by Araclon Biotech SL, H2 2018
  • Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by ArmaGen Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Asceneuron SA, H2 2018
  • Alzheimer's Disease - Pipeline by AstraZeneca Plc, H2 2018
  • Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H2 2018
  • Alzheimer's Disease - Pipeline by Auritec Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Avanir Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H2 2018
  • Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Axxam SpA, H2 2018
  • Alzheimer's Disease - Pipeline by AZTherapies Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Bactevo Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Beactica AB, H2 2018
  • Alzheimer's Disease - Pipeline by Berg LLC, H2 2018
  • Alzheimer's Disease - Pipeline by BioArctic AB, H2 2018
  • Alzheimer's Disease - Pipeline by Biogen Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H2 2018
  • Alzheimer's Disease - Pipeline by BioXcel Therapeutics Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2018
  • Alzheimer's Disease - Pipeline by Bolder Biotechnology Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Co, H2 2018
  • Alzheimer's Disease - Pipeline by Bsim2, H2 2018
  • Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Cardax Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Celon Pharma SA, H2 2018
  • Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Clera Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Cognosci Inc, H2 2018
  • Alzheimer's Disease - Pipeline by CohBar Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Corium International Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H2 2018
  • Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H2 2018
  • Alzheimer's Disease - Pipeline by Cotinga Pharmaceuticals Inc, H2 2018

List of Figures

  • Number of Products under Development for Alzheimer's Disease, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H2 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 25, 56, 53, 3, 276, 102 and 11 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 41 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Alzheimer's Disease - Overview
  • Alzheimer's Disease - Therapeutics Development
  • Alzheimer's Disease - Therapeutics Assessment
  • Alzheimer's Disease - Companies Involved in Therapeutics Development
  • Alzheimer's Disease - Drug Profiles
  • Alzheimer's Disease - Dormant Projects
  • Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research